课题基金 / 基金详情

Design and evaluation of the physical-chemical -material properties parameters: Strategically expanding a prodrug platform for controlled drug delivery

Design and evaluation of the physical-chemical -material properties parameters: Strategically expanding a prodrug platform for controlled drug delivery
物理化学材料特性参数的设计和评估:战略性扩展用于受控药物输送的前药平台
批准号:
556570-2020
负责人:
Sheardown, Heather
金额:
$12.48万
依托单位:
依托单位国家:
加拿大
项目类别:
Alliance Grants
财政年份:
2020
资助国家:
加拿大
项目状态:
已结题
起止时间:
2020-01-01 至 2021-12-31

项目摘要

项目成果

Sheardown, Heather的其他基金

相似基金

相关文献

中文摘要
翻译
改进药物输送的新策略的开发有可能显著改善患者的预后。涟漪治疗公司开发了一种开发植入物的新方法,其基础是发现前药物(药物的非活性版本)可以加工成植入物,而不需要使用聚合物将植入物保持在一起并控制药物的释放速度。这通过更有效地控制药物从植入物中释放的方式减少了治疗患者所需的药量,并防止患者暴露在外来聚合物中。在这笔赠款中,Ripple Treeutics公司对一种名为皮质类固醇的药物的发现将扩展到其他将受益于受控给药的药物类别。将使用一种工程方法来制备完全由前药物制成的植入物,这些药物使用的药物是青光眼治疗和阿片类药物滥用障碍的标准护理。还将评估使用前体药物作为控制其他药物释放的载体系统。将对这些植入物的材料特性进行评估。将进行研究,以确定这些植入物是否可以预测地控制药物释放,并将制备和表征原型。植入材料的安全性也将得到确认。该项目的成功完成将加快为加拿大和国际患者开发新的治疗方案,提高生活质量和拯救生命。
英文摘要
The development of new strategies to improve drug delivery has the potential to significantly improve patient outcomes. Ripple Therapeutics has developed a new approach to developing implants based on a discovery that prodrugs (an inactive version of a drug) can be processed into an implant without the use of a polymer to hold the implant together and control the release rate of the drug. This reduces the amount of drug needed to treat patients by more efficiently controlling how the drug is released from the implant, and prevents exposure of the patient to foreign polymers. In this grant, the discovery that Ripple Therapeutics has made with a class of drugs called corticosteroids will be expanded to other drug classes that would benefit from controlled delivery. An engineering approach will be used to prepare implants made solely of prodrugs using drugs that are standard of care for glaucoma treatment and opioid abuse disorder. The use of prodrugs as a carrier system for controlling the release of other drugs will also be evaluated. The material characteristics of these implants will be assessed. Studies will be performed to determine if these implants can predictably control drug release and prototypes will be prepared and characterized. Safety of the implant materials will also be confirmed. The successful completion of this project will accelerate the development of new treatment options for patients in Canada and internationally, improving quality of life and saving lives.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Changing Ocular Delivery Paradigms
  • 批准号:
    RGPIN-2018-06746
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $3.35万
  • 财政年份:
    2022
  • 负责人:
    Sheardown, Heather
  • 依托单位:
Ophthalmic Biomaterials and Drug Delivery Systems
  • 批准号:
    CRC-2020-00309
  • 项目类别:
    Canada Research Chairs
  • 资助金额:
    $14.57万
  • 财政年份:
    2022
  • 负责人:
    Sheardown, Heather
  • 依托单位:
Injectable, gelable and degradable system for protein delivery in partnership with Mannin
  • 批准号:
    570781-2021
  • 项目类别:
    Alliance Grants
  • 资助金额:
    $22.9万
  • 财政年份:
    2021
  • 负责人:
    Sheardown, Heather
  • 依托单位:
Ophthalmic Biomaterials And Drug Delivery Systems
  • 批准号:
    CRC-2014-00118
  • 项目类别:
    Canada Research Chairs
  • 资助金额:
    $7.29万
  • 财政年份:
    2021
  • 负责人:
    Sheardown, Heather
  • 依托单位:
国内基金
海外基金
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
  • 批准号:
    82370885
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨
  • 依托单位:
基于重要农地保护LESA(Land Evaluation and Site Assessment)体系思想的高标准基本农田建设研究
  • 批准号:
    41340011
  • 项目类别:
    专项基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2013
  • 负责人:
    钱凤魁
  • 依托单位:
基于观测角度的汉语名词性隐喻逻辑释义和评价方法研究
  • 批准号:
    61075058
  • 项目类别:
    面上项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2010
  • 负责人:
    苏畅
  • 依托单位:
面向认知网络的自律计算模型及评价方法研究
  • 批准号:
    60973027
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2009
  • 负责人:
    王慧强
  • 依托单位: